The 17-Gene Genomic Prostate Score Assay Is Prognostic for Biochemical Failure in Men With Localized Prostate Cancer...

Area of Science:

• Oncology
• Genomics
• Radiation Oncology

Background:

• Localized prostate cancer (PCa) management often involves radiation therapy (RT).
• Accurate prognostication is crucial for tailoring treatment and predicting long-term outcomes.
• Genomic assays offer potential to refine risk stratification beyond traditional clinicopathologic factors.

Purpose of the Study:

• To evaluate the association between the Oncotype DX Genomic Prostate Score (GPS) assay and long-term outcomes in men with localized PCa treated with RT.
• To determine if the GPS assay is prognostic for biochemical failure (BCF), distant metastasis (DM), and PCa-specific mortality.

Main Methods:

• Retrospective analysis of 450 men with localized PCa treated with definitive RT (2010-2016).
• Assessment of the association between GPS results and time to BCF (Phoenix criteria), DM, and PCa-specific mortality.
• Cox proportional hazards regression models were used for univariable and multivariable analyses, adjusting for clinicopathologic covariates.

Main Results:

• A strong univariable association was found between GPS result and time to BCF (HR=3.08, P<.001), which remained significant in multivariable analyses.
• The GPS assay was also strongly prognostic for time to DM (HR=5.19, P<.001) and PCa-specific mortality (HR=13.07, P<.001).
• The GPS assay demonstrated prognostic value across different racial groups, with no significant difference in its predictive ability between Black and White patients.

Conclusions:

• The Genomic Prostate Score (GPS) assay is a strong prognostic marker for biochemical failure in men with localized prostate cancer treated with radiation therapy.
• The GPS assay also predicts long-term outcomes such as distant metastasis and prostate cancer-specific mortality.
• These findings support the utility of the GPS assay in risk stratification for patients undergoing radiation therapy for prostate cancer.